Currently, there are no FDA-approved targeted therapies specifically for NRG1 fusions, but treatments targeting the NRG1/ErbB signaling pathway have shown both preclinical and clinical efficacy in several tumor types [75]. This evidence concerns the gene EGFR and neoplasm.